论文部分内容阅读
目的探讨股动脉介入置管灌注尿激酶、硫辛酸、前列地尔治疗糖尿病足的临床应用价值。方法选取医院收治的糖尿病足患者100例为研究对象,随机分为对照组和观察组,每组50例。对照组按传统综合治疗方案治疗,观察组在对照组治疗基础上予股动脉介入置管行尿激酶、硫辛酸、前列地尔等药物持续灌注。比较2组临床症状改善情况、溃疡愈合时间及住院时间。结果观察组患者临床症状改善率为86.74%,高于对照组的60.37%(P<0.05)。2组患者治疗后ABI升高,VPT下降,与治疗前比较差异均有统计学意义(P<0.05)。观察组患者溃疡愈合时间为(60.14±8.2)d,短于对照组的(91.05±19.87)d(P<0.05)。观察组患者住院时间为(29.41±4.5)d,短于对照组的(44.02±7.25)d(P<0.05)。结论股动脉介入置管灌注尿激酶、硫辛酸、前列地尔治疗糖尿病足临床症状改善率高,有利于缩短溃疡愈合时间及住院时间,有较大的临床推广应用价值。
Objective To investigate the clinical value of percutaneous catheter perfusion of urokinase, lipoic acid and alprostadil in the treatment of diabetic foot. Methods 100 cases of diabetic foot admitted to hospital were selected as research object and randomly divided into control group and observation group, 50 cases in each group. The control group was treated by the traditional comprehensive treatment plan. The observation group was given perfusion of urokinase, lipoic acid, alprostadil and other drugs on the basis of the treatment of the control group. The clinical symptom improvement, ulcer healing time and hospital stay were compared between the two groups. Results The improvement rate of clinical symptoms in observation group was 86.74%, which was higher than that in control group (60.37%, P <0.05). ABI increased and VPT decreased after treatment in both groups, with statistical significance (P <0.05). The healing time of ulcer in the observation group was (60.14 ± 8.2) d, which was shorter than that of the control group (91.05 ± 19.87) d (P <0.05). The length of hospital stay in observation group was (29.41 ± 4.5) d, shorter than that in control group (44.02 ± 7.25) d (P <0.05). Conclusion Percutaneous catheter perfusion of urokinase, lipoic acid and alprostadil for the treatment of diabetic foot with femoral artery perfusion can improve the clinical symptoms of diabetic foot, which will help to shorten the healing time and hospital stay of the ulcer. It is of great value in clinical application.